UnknownNCT04377867
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies
Studying Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Marmara University
- Principal Investigator
- Safa Baris, M.D.Marmara University
- Intervention
- Abatacept Injection [Orencia](drug)
- Enrollment
- 30 enrolled
- Eligibility
- 1-60 years · All sexes
- Timeline
- 2020 – 2023
Study locations (1)
- Marmara University, Istanbul, Pendik, Turkey (Türkiye)
Collaborators
The Scientific and Technological Research Council of Turkey
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04377867 on ClinicalTrials.govOther trials for Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency
Additional recruiting or active studies for the same condition.
See all trials for Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency →